ArticleDiscover oncology2026
Sarcomatoid adrenocortical carcinoma with aggressive disease course: a rare case report and literature review.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSarcomatoid Adrenocortical Carcinoma (SAC) is an extremely rare, highly aggressive, and poorly differentiated subtype of Adrenocortical Carcinoma (ACC). To date, only 38 cases have been reported worldwide. No standardized clinical diagnosis and treatment protocols have been established, and the prognosis of affected patients is extremely poor. This study reports a case of SAC in a 60-year-old female patient presenting with an abdominal mass, aiming to analyze the clinical characteristics, diagnosis, and treatment features of this rare tumor. CASE PRESENTATION: A 60-year-old female was admitted to our hospital due to an upper abdominal mass. Imaging examinations revealed a cystic-solid space-occupying lesion in the left retroperitoneum, and the tumor was highly suspected to be of adrenal cortical origin preoperatively. Given the rapid disease progression and the patient's strong demand for urgent surgery, preoperative endocrine function examinations including cortisol, aldosterone, sex hormones and catecholamines were not performed. Laparotomy with complete tumor resection was Sarcomatoid Adrenocortical Carcinomasubsequently performed, and the final pathological diagnosis was SAC. The tumor was composed of 60% carcinomatous components and 40% high-grade sarcomatous components, classified as Fuhrman nuclear grade IV, with extensive parenchymal necrosis and vascular tumor thrombi observed in the lesion. One month after surgery, the patient developed extensive peritoneal metastasis and ascites, and eventually died on the 42nd day postoperatively.
conclusionSAC has non-specific manifestations and high diagnostic difficulty, with histopathology plus immunohistochemistry as the diagnostic gold standard. Highly invasive and rapidly progressive, it is mainly treated with surgical resection by following ACC protocols, yet their pathological features differ significantly. Given the extremely limited number of reported cases, current evidence is insufficient to either support or refute the efficacy of mitotane for SAC, and more multicenter large-sample studies are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.